Market Report -- In Play (BIIB)
November 18, 2009 4:02 PM ET
Biogen Idec and Genenech receive a complete response from the FDA for Rituxan for chronic lymphocytic leukemia Genentech, a wholly-owned member of the Roche, and BIIB announced that the FDA issued a complete response on the companies' applications for Rituxan plus fludarabine and cyclophosphamide for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia. T
he FDA has not requested any new data to complete its review of these applications. Genentech and BIIB will continue final label discussions with the FDA and are committed to making Rituxan in combination with FC an FDA-approved option for people with CLL.
Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles
Back to News Home
- MSN Money
- Search MSN Money
- Message Boards
- Site Status
For today's top Money video click here
E-mail this article
Print-friendly version
Discuss this article